So should Cullinan Therapeutics ( NASDAQ:CGEM) shareholders be worried about its cash burn? For the purposes of this article, cash burn is the annual rate at which an unprofitable company spends cash ...

Cullinan Therapeutics (NASDAQ:CGEM – Get Free Report) had its price objective boosted by investment analysts at HC Wainwright from $28.00 to $33.00 in a research note issued to investors on Wednesday, ...

Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Get Free Report)’s share price gapped up before the market opened on Wednesday after HC Wainwright raised their price target on the stock from $28.00 to $33.

Cullinan Therapeutics and its partner Taiho Pharmaceutical have reported a win for zipalertinib, with the primary endpoint of a Phase IIb trial being met. The data, which include a positive safety ...

Halcones Precious Metals Corp. (TSXV: HPM) (the "Company” or "Halcones”) is pleased to announce that it has completed the transactio ...

CAMBRIDGE, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on ...

In a report released today, Julian Harrison from BTIG maintained a Buy rating on Cullinan Management (CGEM – Research Report), with a price ...

Taiho Pharmaceutical Co., Ltd., Taiho Oncology, Inc., and Cullinan Therapeutics, Inc. have announced the successful outcome ...

Taiho Pharmaceutical and Taiho Oncology reported that a Phase 1/2 study of the drug zipalertinib met its primary endpoint of overall response rate in a study of EGFR lung cancer patients. The drug was ...

H.C. Wainwright raised the firm’s price target on Cullinan Therapeutics (CGEM) to $33 from $28 and keeps a Buy rating on the shares after the ...

Cullinan Therapeutics has announced that its lead asset has aced a midstage lung cancer trial—but the biotech is keeping the ...

With the devastation of Tuesday night's fire in Ovid now setting in for the folks who live there, town leaders are calling on state officials for assistance with rebuilding and adequate resources for ...